Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study.
Force G, Ghout I, Ropers J, Carcelain G, Marigot-Outtandy D, Hahn V, Darchy N, Defferriere H, Bouaziz-Amar E, Carlier R, Dorgham K, Callebert J, Peytavin G, Delaugerre C, de Truchis P; NEURO+3 STUDY GROUP. Force G, et al. Among authors: de truchis p. J Antimicrob Chemother. 2021 Feb 11;76(3):743-752. doi: 10.1093/jac/dkaa473. J Antimicrob Chemother. 2021. PMID: 33179033
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group. Duvivier C, et al. J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18. J Antimicrob Chemother. 2008. PMID: 18641035 Clinical Trial.
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.
HIV-CAUSAL Collaboration; Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA. HIV-CAUSAL Collaboration, et al. AIDS. 2010 Jan 2;24(1):123-37. doi: 10.1097/QAD.0b013e3283324283. AIDS. 2010. PMID: 19770621 Free PMC article.
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, Verdon R, de Truchis P, May T, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 Study Group. Gallien S, et al. Among authors: de truchis p. J Antimicrob Chemother. 2011 Sep;66(9):2099-106. doi: 10.1093/jac/dkr269. Epub 2011 Jun 28. J Antimicrob Chemother. 2011. PMID: 21712241 Clinical Trial.
[Aging and HIV infection: 4 years follow-up of 149 HIV infected patients older than 60 years in West Paris agglomeration (COREVIH Île-de-France Ouest)].
Flexor G, Zucman D, Berthé H, Meier F, Force G, Greder-Belan A, Billy C, Dupont C, Mortier E, Bizard A, Rouveix E, de Truchis P; le COREVIH Île-de-France Ouest. Flexor G, et al. Among authors: de truchis p. Presse Med. 2013 May;42(5):e145-52. doi: 10.1016/j.lpm.2012.11.005. Epub 2013 Feb 20. Presse Med. 2013. PMID: 23433913 French.
Transmitted drug resistance in French HIV-2-infected patients.
Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort. Charpentier C, et al. AIDS. 2013 Jun 19;27(10):1671-4. doi: 10.1097/QAD.0b013e32836207f3. AIDS. 2013. PMID: 23595155
240 results